Targeting TNFα‑mediated cytotoxicity using thalidomide after experimental cardiac arrest in rats: An exploratory study

  • Authors:
    • Abigail A. Palmer
    • Jason P. Stezoski
    • Keri Janesko‑Feldman
    • Patrick M. Kochanek
    • Tomas Drabek
  • View Affiliations

  • Published online on: April 8, 2022     https://doi.org/10.3892/etm.2022.11307
  • Article Number: 380
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cardiac arrest (CA) results in a central and systemic cytokine and inflammatory response. Thalidomide has been reported to be neuroprotective by selectively decreasing TNFα synthesis. We hypothesized that thalidomide would decrease the systemic and organ‑specific TNFα/cytokine response and biomarkers of injury in rats subjected to 10 min CA. Naïves, CA treated with vehicle (CA) and CA treated with thalidomide (50 mg/kg; CA+T) were studied (n=6 per group). TNFα and key cytokines were assessed at 3 h after resuscitation in the cortex, hippocampus, striatum, cerebellum, plasma, heart and lung. Neuron specific enolase (NSE), S100b, cardiac troponin T (cTnT) and intestinal fatty acid binding protein (IFABP) were used to assess neuronal, glial, cardiac and intestinal damage, respectively. CA increased TNFα and multiple pro‑inflammatory cytokines in plasma and selected tissues with no differences between the CA and CA+T groups in any region. NSE, S100b, cTnT and IFABP were increased after CA or CA+T vs. in the naïve group (all P<0.05) without significant differences between the CA and CA+T groups. In conclusion, CA resulted in a TNFα and cytokine response, with increased biomarkers of organ injury. Notably, thalidomide at a dose reported to improve the outcome in in vivo models of brain ischemia did not decrease TNFα or cytokine levels in plasma, brain or extracerebral organs, or biomarkers of injury. Although CA at 3 h post resuscitation produces a robust TNFα response, it cannot be ruled out that an alternative dosing regimen or assessment at other time‑points might yield different results. The marked systemic and regional cytokine response to CA remains a potential therapeutic target.
View Figures
View References

Related Articles

Journal Cover

June-2022
Volume 23 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Palmer AA, Stezoski JP, Janesko‑Feldman K, Kochanek PM and Drabek T: Targeting TNFα‑mediated cytotoxicity using thalidomide after experimental cardiac arrest in rats: An exploratory study. Exp Ther Med 23: 380, 2022
APA
Palmer, A.A., Stezoski, J.P., Janesko‑Feldman, K., Kochanek, P.M., & Drabek, T. (2022). Targeting TNFα‑mediated cytotoxicity using thalidomide after experimental cardiac arrest in rats: An exploratory study. Experimental and Therapeutic Medicine, 23, 380. https://doi.org/10.3892/etm.2022.11307
MLA
Palmer, A. A., Stezoski, J. P., Janesko‑Feldman, K., Kochanek, P. M., Drabek, T."Targeting TNFα‑mediated cytotoxicity using thalidomide after experimental cardiac arrest in rats: An exploratory study". Experimental and Therapeutic Medicine 23.6 (2022): 380.
Chicago
Palmer, A. A., Stezoski, J. P., Janesko‑Feldman, K., Kochanek, P. M., Drabek, T."Targeting TNFα‑mediated cytotoxicity using thalidomide after experimental cardiac arrest in rats: An exploratory study". Experimental and Therapeutic Medicine 23, no. 6 (2022): 380. https://doi.org/10.3892/etm.2022.11307